Home/Filings/4/0001214659-20-007417
4//SEC Filing

Wasoff Evan L 4

Accession 0001214659-20-007417

CIK 0001625288other

Filed

Aug 20, 8:00 PM ET

Accepted

Aug 21, 1:16 PM ET

Size

8.7 KB

Accession

0001214659-20-007417

Insider Transaction Report

Form 4
Period: 2020-08-19
Wasoff Evan L
Chief Financial Officer
Transactions
  • Award

    Options to purchase common stock (right to buy)

    2020-08-19+1,500,0001,500,000 total
    Exercise: $0.08From: 2020-08-19Exp: 2027-08-19Common Stock (1,500,000 underlying)
Holdings
  • Common Stock

    1,000,000
  • Stock option - right to buy

    Exercise: $0.66From: 2018-10-26Exp: 2025-10-26Common Stock (200,000 underlying)
    200,000
  • Stock option - right to buy

    Exercise: $0.54From: 2018-07-25Exp: 2025-07-25Common Stock (420,000 underlying)
    420,000
Footnotes (2)
  • [F1]Options to purchase 1,000,000 shares are vested and immediately exercisable. Options to purchase 500,000 shares vest over 4 quarters beginning September 30, 2020.
  • [F2]Granted in lieu of cash compensation.

Issuer

NEXIEN BIOPHARMA, INC.

CIK 0001625288

Entity typeother

Related Parties

1
  • filerCIK 0001719738

Filing Metadata

Form type
4
Filed
Aug 20, 8:00 PM ET
Accepted
Aug 21, 1:16 PM ET
Size
8.7 KB